Data Sheet | February 21, 2025
NULISAseq™ Inflammation Panel AQ
Get the Resource
Download NowWith the NULISAseq Inflammation Panel Absolute Quantification (AQ), Sapient can deliver precise quantitative measurements for over 150 key protein biomarkers of inflammation and immune response. The NULISA™ platform is optimized to detect low-abundance cytokines and other key protein targets in both normal and disease states, providing a robust method to track immune changes in longitudinal studies or following therapeutic intervention in clinical trials.
The Inflammation Panel AQ simultaneously measures key inflammation-related targets – encompassing cytokines, chemokines, growth factors, and other inflammatory mediators – to provide a targeted but comprehensive approach to identify critical pathways and uncover novel therapeutic opportunities.
As a Certified Service Provider of Alamar Biosciences NULISA panels and assays, you can tap Sapient’s deep expertise in Alamar’s technologies and in multi-omics data and insight generation to obtain robust measures of hard-to-assay biomarkers that represent important modulators of immune processes.
Download the data sheet to learn how the NULISAseq Inflammation Panel Absolute Quantification (AQ) enables:
- >99% quantifiability in normal samples to detect subtle changes from baseline or after treatment
- Robust measure over 9 logs of dynamic range for absolute quantification of both high-abundance proteins and low-abundance analytes
- High reproducibility with median CVs <10% across measures
You can also see how this NULISA panel complements our mass spectrometry-based proteomics services by allowing for absolute quantification of protein biomarkers and novel signatures discovered in a study.